KRS Capital Management LLC Increases Holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG)

KRS Capital Management LLC grew its holdings in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG) by 19.8% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,240 shares of the medical equipment provider’s stock after buying an additional 205 shares during the quarter. KRS Capital Management LLC’s holdings in Intuitive Surgical were worth $495,000 at the end of the most recent reporting period.

Several other hedge funds have also recently made changes to their positions in the business. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA raised its position in shares of Intuitive Surgical by 0.3% during the 4th quarter. Loring Wolcott & Coolidge Fiduciary Advisors LLP MA now owns 8,899 shares of the medical equipment provider’s stock valued at $3,002,000 after buying an additional 27 shares in the last quarter. Advance Capital Management Inc. raised its position in Intuitive Surgical by 3.8% in the 1st quarter. Advance Capital Management Inc. now owns 740 shares of the medical equipment provider’s stock worth $295,000 after purchasing an additional 27 shares during the period. Sheaff Brock Investment Advisors LLC raised its position in Intuitive Surgical by 1.3% in the 4th quarter. Sheaff Brock Investment Advisors LLC now owns 2,226 shares of the medical equipment provider’s stock worth $751,000 after purchasing an additional 29 shares during the period. Liberty Capital Management Inc. raised its position in Intuitive Surgical by 3.8% in the 4th quarter. Liberty Capital Management Inc. now owns 815 shares of the medical equipment provider’s stock worth $275,000 after purchasing an additional 30 shares during the period. Finally, NBC Securities Inc. raised its position in Intuitive Surgical by 34.4% in the 1st quarter. NBC Securities Inc. now owns 121 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 31 shares during the period. 83.64% of the stock is currently owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the completion of the transaction, the director now owns 25,319 shares in the company, valued at approximately $9,385,753.30. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, Director Alan J. Levy sold 2,000 shares of the stock in a transaction dated Tuesday, April 23rd. The shares were sold at an average price of $370.70, for a total value of $741,400.00. Following the sale, the director now directly owns 25,319 shares of the company’s stock, valued at approximately $9,385,753.30. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of the stock in a transaction dated Wednesday, June 12th. The shares were sold at an average price of $421.06, for a total transaction of $589,484.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 17,956 shares of company stock worth $6,927,011. 0.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on ISRG. Jefferies Financial Group upped their target price on shares of Intuitive Surgical from $365.00 to $375.00 and gave the stock a “hold” rating in a research note on Friday, April 19th. Robert W. Baird dropped their target price on shares of Intuitive Surgical from $440.00 to $436.00 and set an “outperform” rating on the stock in a research note on Friday, April 19th. Stifel Nicolaus upped their target price on shares of Intuitive Surgical from $420.00 to $430.00 and gave the stock a “buy” rating in a research note on Monday, April 8th. Piper Sandler upped their target price on shares of Intuitive Surgical from $425.00 to $435.00 and gave the stock an “overweight” rating in a research note on Friday, April 19th. Finally, BTIG Research increased their price objective on shares of Intuitive Surgical from $412.00 to $421.00 and gave the company a “buy” rating in a research note on Friday, April 19th. Five equities research analysts have rated the stock with a hold rating and fourteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $403.67.

Intuitive Surgical Price Performance

Shares of Intuitive Surgical stock traded down $0.26 during trading hours on Friday, hitting $444.85. The company had a trading volume of 3,106,192 shares, compared to its average volume of 1,372,778. The company’s 50-day moving average is $403.83 and its two-hundred day moving average is $382.69. Intuitive Surgical, Inc. has a twelve month low of $254.85 and a twelve month high of $447.11. The company has a market cap of $157.79 billion, a P/E ratio of 80.30, a price-to-earnings-growth ratio of 5.75 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG) last issued its quarterly earnings results on Thursday, April 18th. The medical equipment provider reported $1.50 earnings per share for the quarter, topping analysts’ consensus estimates of $1.40 by $0.10. The firm had revenue of $1.89 billion during the quarter, compared to analysts’ expectations of $1.87 billion. Intuitive Surgical had a net margin of 27.16% and a return on equity of 12.91%. Intuitive Surgical’s quarterly revenue was up 11.5% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.00 EPS. Sell-side analysts expect that Intuitive Surgical, Inc. will post 4.8 EPS for the current year.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.